|Roman Nowicki |
The topical calcineurin inhibitors (TCIs), tacrolimus ointment (Protopic®) and pimecrolimus cream (Elidel®), are a new class of topical immunomodulators. Their mechanism of action is based on calcineurin inhibition, which results in decreased T-cell activation and inflammatory cytokine release. TCIs are safe and effective for treatment of atopic dermatitis (AD) and others inflammatory diseases in adults and children. The most common adverse events (AEs) associated with use of TCIs are a transient burning sensation, pruritus and erythema at the site of application. Exposure of the skin to ultraviolet (UV) light should be minimized while using TCI’s.
Unlike topical corticosteroid agents, TCIs do not cause a reduction in collagen synthesis or skin thickness. TCIs may be safely used for many months on all skin areas, including sensitive skin regions such as the face, eyelid area, neck and intertriginous areas. In addition, they offer solutions for steroid-phobic patients.
keywords: MIK, takrolimus, pimekrolimus, AZS, TCI’s, tacrolimus, pimecrolimus, AD
pages: from 24 to 28